Base de dados : LILACS
Pesquisa : D02.540.505.810 [Categoria DeCS]
Referências encontradas : 120 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 12 ir para página                         

  1 / 120 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Alberti, Luiz Ronaldo
Texto completo
Id: biblio-1001151
Autor: Menezes, Mariana Campos Souza; Vasconcellos, Leonardo de Souza; Nunes, Cristiana Buzelin; Alberti, Luiz Ronaldo.
Título: Evaluation of the use of tacrolimus ointment for the prevention of hypertrophic scars in experimental model
Fonte: An. bras. dermatol;94(2):164-171, Mar.-Apr. 2019. tab, graf.
Idioma: en.
Resumo: Abstract BACKGROUND: Tacrolimus, for its activity on modulation of collagen production and fibroblast activity, may have a role in the prevention of hypertrophic scars. OBJECTIVES: Evaluate macroscopic, microscopic, metabolic, laboratory effects and side effects of the use of topical tacrolimus ointment, in different concentrations, in the prevention of hypertrophic scars. METHODS: Twenty-two rabbits were submitted to the excision of 2 fragments of 1 cm of each ear, 4 cm apart, down to cartilage. The left ear of the animals was standardized as control and Vaseline applied twice a day. The right ear received tacrolimus ointment, at concentrations of 0.1% on the upper wound and 0.03% on the lower wound, also applied twice a day. Macroscopic, microscopic, laboratory criteria and the animals' weight were evaluated after 30 days of the experiment. RESULTS: Wounds treated with tacrolimus, at concentrations of 0.1% and 0.03%, when compared to control, showed a lower average degree of thickening (p = 0.048 and p <0.001, respectively). The average of scar thickness and lymphocyte, neutrophil and eosinophil concentrations are lower in the treated wounds compared to the control (p <0.001, p=0.022, p=0.007, p=0.044, respectively). The mean concentration of lymphocytes is lower in wounds treated with a higher concentration of the drug (p=0.01). STUDY LIMITATIONS: experiment lasted only 30 days. CONCLUSIONS: Tacrolimus at the 2 concentrations evaluated reduced the severity of inflammatory changes and positively altered the macroscopic aspect of the scar in the short term. Its use was shown to be safe, with no evidence of systemic or local adverse effects.
Descritores: Tacrolimo/uso terapêutico
Inibidores de Calcineurina/uso terapêutico
-Pomadas
Ureia/sangue
Albumina Sérica/análise
Albumina Sérica/efeitos dos fármacos
Administração Tópica
Tacrolimo/administração & dosagem
Tacrolimo/farmacologia
Cicatriz Hipertrófica/patologia
Cicatriz Hipertrófica/prevenção & controle
Contagem de Linfócitos
Creatinina/sangue
Alanina Transaminase/efeitos dos fármacos
Alanina Transaminase/sangue
Modelos Animais de Doenças
Orelha Externa/patologia
Eritema/patologia
Inibidores de Calcineurina/administração & dosagem
Inibidores de Calcineurina/farmacologia
Inflamação/patologia
Inflamação/prevenção & controle
Limites: Animais
Masculino
Coelhos
Tipo de Publ: Estudos de Avaliação
Responsável: BR1.1 - BIREME


  2 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1039050
Autor: Guo, Jian; Fang, Huihui; Gui, Shuangying; Huang, Yuzhe.
Título: Solid dispersion-based pellet for colon delivery of tacrolimus through time- and pH-dependent layer coating: preparation, in vitro and in vivo studies
Fonte: Braz. J. Pharm. Sci. (Online);55:e17309, 2019. tab, graf.
Idioma: en.
Projeto: National Natural Science Foundation of China.
Resumo: The intent of the present investigation is to develop and evaluate colon-specific coated tacrolimus solid dispersion pellet (SDP) that retards drug release in the stomach and small intestine but progressively releases in the colon. Tacrolimus-SDP was prepared by extrusion-spheronization technology and optimized by the micromeritic properties including flowability, friability, yields and dissolution rate. Subsequently, the pH-dependent layer (Eudragit L30D55) and time-dependent layer (Eudragit NE30D and L30D55) were coated on the SDP to form tacrolimus colon-specific pellets (CSP) using a fluidized bed coater. Under in vitro gradient pH environment, tacrolimus only released from CSP after changing pH to 6.8 and then quickly released in the phosphate buffer solution of pH 7.2. The Cmax of CSP was 195.68 ± 3.14 ng/mL at Tmax 4.5 ± 0.24 h where as in case of SDP, the Cmax was 646.16 ± 8.15 ng/mL at Tmax 0.5 ± 0.03 h, indicating the ability of CSP targeted to colon. The highest area under the curve was achieved 2479.58 ± 183.33 ng·h/mL for SDP, which was 2.27-fold higher than tacrolimus suspension. However, the best biodistribution performance was achieved from CSP. In conclusion, SDP combining of pH- and time-dependent approaches was suitable for targeted delivery of tacrolimus to colon.
Descritores: Técnicas In Vitro/classificação
Tacrolimo/análise
Fator de Crescimento de Hepatócito/farmacocinética
Colo/metabolismo
-Colite Ulcerativa/prevenção & controle
Sistemas de Liberação de Medicamentos/efeitos adversos
Concentração de Íons de Hidrogênio
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  3 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-837945
Autor: Cakici, Ozgur; Karadag, Remzi; Bayramlar, Huseyin; Ozkanli, Seyma; Uzuncakmak, Tugba Kevser; Karadag, Ayse Serap.
Título: Periorbital discoid lupus: a rare localization in a patient with systemic lupus erythematosus
Fonte: An. bras. dermatol;91(5,supl.1):122-124, Sept.-Oct. 2016. graf.
Idioma: en.
Resumo: Abstract A 40-year-old female patient with a 5-year history of systemic lupus erythematosus was referred to our policlinic with complaints of erythema, atrophy, and telangiectasia on the upper eyelids for 8 months. No associated mucocutaneous lesion was present. Biopsy taken by our ophthalmology department revealed discoid lupus erythematosus. Topical tacrolimus was augmented to the systemic therapeutic regimen of the patient, which consisted of continuous antimalarial treatment and intermittent corticosteroid drugs. We observed no remission in spite of the 6-month supervised therapy. Periorbital discoid lupus erythematosus is very unusual and should be considered in the differential diagnosis of erythematous lesions of the periorbital area..
Descritores: Lúpus Eritematoso Discoide/patologia
Doenças Palpebrais/patologia
Lúpus Eritematoso Sistêmico/patologia
-Biópsia
Tacrolimo/uso terapêutico
Corticosteroides/uso terapêutico
Doenças Raras
Pálpebras/patologia
Imunossupressores/uso terapêutico
Limites: Seres Humanos
Feminino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  4 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-781375
Autor: Sisti, Andrea; Sisti, Giovanni; Oranges, Carlo Maria.
Título: Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review
Fonte: An. bras. dermatol;91(2):187-195, Mar.-Apr. 2016. tab.
Idioma: en.
Resumo: Abstract Thus far, several small studies and case reports on the use of topical immunomodulators in vitiligo have been published. We undertook a comprehensive literature review, searching for studies evaluating clinical response to tacrolimus topical therapy for vitiligo. A search was performed on PubMed/Medline using the term “vitiligo”, combined with “topical” and “ointment”. Our inclusion criteria were: use of tacrolimus ointment as monotherapy to treat vitiligo. We found 29 studies from 2002 to 2014. Overall, 709 patients were treated in 29 studies. Pooling the lesions, 50% repigmentation of vitiligo patches was never achieved before 2 months of treatment, with a peak after 6 months of therapy. The best results were obtained on lesions of the cephalic region, especially the face, with tacrolimus 0.1% ointment two times daily. The percentage of non-responsive patients ranged from 0% to 14%. Treatment was generally well-tolerated; only localized adverse effects were reported. Our objective was to verify the effectiveness and safety of tacrolimus ointment monotherapy. It has good efficacy and tolerability. At present, only small trials and case series are available in the literature. Further, standardized investigations on a larger number of patients are needed.
Descritores: Vitiligo/tratamento farmacológico
Pigmentação da Pele/efeitos dos fármacos
Tacrolimo/uso terapêutico
Imunossupressores/uso terapêutico
-Pomadas
Administração Cutânea
Reprodutibilidade dos Testes
Resultado do Tratamento
Limites: Seres Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  5 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-973690
Autor: Méndez-Abad, Paula; Zafra-Rodríguez, Pamela.
Título: Miocardiopatía hipertrófica en un recién nacido pretérmino con madre trasplantada renal / Hypertrophic cardiomyopathy in preterm newborn with kidney transplanted mother
Fonte: Arch. argent. pediatr;116(6):749-752, dic. 2018. ilus.
Idioma: es.
Resumo: La miocardiopatía hipertrófica en el recién nacido es una entidad poco frecuente y de etiología heterogénea. Se han descrito formas transitorias en hijos de madres con diabetes gestacional y en recién nacidos pretérminos expuestos a corticoides tanto prenatal como posnatalmente. Se presenta un caso de un recién nacido pretérmino, hijo de madre trasplantada renal al que se le detectó una miocardiopatía hipertrófica y que había estado expuesto prenatalmente a corticoides y tacrolimus que recibía la madre como tratamiento inmunosupresor. Ambos fármacos cruzan la barrera placentaria y, al llegar al feto, podrían haber favorecido su desarrollo. La miocardiopatía hipertrófica puede ser un efecto secundario poco común del tratamiento con tacrolimus en adultos y niños, y es reversible al retirarlo. En nuestro conocimiento, es el primer caso publicado de miocardiopatía hipertrófica transitoria tras la exposición fetal tanto a corticoides como a tacrolimus en un hijo de madre trasplantada renal.

Hypertrophic cardiomyopathy in the newborn is a rare entity with heterogeneous etiology. Transient forms have been described in children of mothers with gestational diabetes and in preterm infants exposed both to prenatal and postnatal corticosteroids. We report a case of a preterm infant son of a mother who received renal transplant in whom hypertrophic cardiomyopathy was detected. He had been prenatally exposed to corticosteroids and tacrolimus that received the mother as immunosuppressive therapy. Both drugs cross the placental barrier and, on reaching the fetus, could have favored its development. Hypertrophic cardiomyopathy may be an uncommon side effect of treatment with tacrolimus in adults and children and it is reversible upon withdrawal. To our knowledge, it is the first published case of transient hypertrophic cardiomyopathy after fetal exposure to both corticosteroids and tacrolimus in the son of a renal transplanted mother.
Descritores: Cardiomiopatia Hipertrófica/induzido quimicamente
Tacrolimo/efeitos adversos
Glucocorticoides/efeitos adversos
Imunossupressores/efeitos adversos
-Placenta/metabolismo
Recém-Nascido Prematuro
Gravidez
Transplante de Rim/métodos
Tacrolimo/administração & dosagem
Tacrolimo/farmacocinética
Glucocorticoides/administração & dosagem
Glucocorticoides/farmacocinética
Imunossupressores/administração & dosagem
Imunossupressores/farmacocinética
Mães
Limites: Seres Humanos
Masculino
Recém-Nascido
Tipo de Publ: Relatos de Casos
Responsável: AR94.1 - Centro de Información Pediatrica


  6 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Abrahao, Marcos de Souza
Texto completo
Id: biblio-827651
Autor: Morello, Ricardo José; Koike, Marcia Kiyomi; Abrahão, Marcos de Souza; Saad, Karen Ruggeri; Saad, Paulo Fernandes; Montero, Edna Frasson de Souza.
Título: Remote ischemic preconditioning and tacrolimus in the fetal small bowel transplant in mice
Fonte: Acta cir. bras;31(10):675-679, Oct. 2016. graf.
Idioma: en.
Resumo: ABSTRACT PURPOSE: To evaluate the effect of remote ischemic preconditioning (IPC-R) in the fetal small bowel transplantation model. METHODS: Two groups were constituted: The Isogenic transplant (ISO, C57BL/6 mice, n=24) and the allogenic transplant (ALO, BALB/c mice, n=24). In each group, the animals were distributed with and without IPC-R. It was obtained the following subgroups: Tx, IPC-R, Fk, IPC-Fk, in both strains. Intestinal grafts were stained with hematoxylin and eosin and immunohistochemically. RESULTS: The graft development evaluation in ISO group showed that IPC-R reduced the development compared with ISO-Tx (5.2±0.4 vs 9.0±0.8) and IPC-R-Fk increased the graft development compared with IPC-R (11.2±0.7 and 10.2±0.8). In ALO group, IPC-Fk increased the development compared with ALO-Tx and ALO with IPC-R (6.0±0.8, 9.0±1.2, 0.0±0.0, 0.5±0.3). The PCNA expression was increased in ISO group treated with Fk and IPC-R compared to other groups (12.2±0.8 vs Tx: 8.8±0.9, IPC-R: 8.0±0.4 and Fk: 9.0±0.6). The graft rejection was lower in groups treated with IPC-R (-18%), Fk (-68%) or both (-61%) compared with ALO-Tx. CONCLUSION: Remote ischemic preconditioning showed benefic effect even associate with Tacrolimus on the development and acute rejection of the fetal small bowel graft in the Isogenic and Allogenic transplants.
Descritores: Transplante de Tecido Fetal/métodos
Tacrolimo/uso terapêutico
Precondicionamento Isquêmico/métodos
Imunossupressores/uso terapêutico
Intestino Delgado/irrigação sanguínea
Intestino Delgado/transplante
-Fatores de Tempo
Transplante Isogênico
Imuno-Histoquímica
Reprodutibilidade dos Testes
Resultado do Tratamento
Proliferação Celular/efeitos dos fármacos
Rejeição de Enxerto/prevenção & controle
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos C57BL
Limites: Animais
Masculino
Feminino
Camundongos
Tipo de Publ: Estudos de Avaliação
Responsável: BR1.1 - BIREME


  7 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1006493
Autor: Acosta, Fabio Rubén; Benítez, María Laura; Oddino, Juan; Lema, Silvia; Loureyro, Juan; Arnoldi, Julia; Stur, Mariela.
Título: Síndrome doloroso por inhibidores de la calcineurina: reporte de 4 casos en pacientes con retrasplante renal / Calcineurin-inhibitor induced pain syndrome: a 4-case report on patients with kidney retransplantation
Fonte: Rev. nefrol. diál. traspl;37(3):137-145, sept. 2017. ilus, tab, graf.
Idioma: es.
Conferência: Apresentado em: ERA-EDTA 54° Congreso Europeo de Nefrología (Madrid, 3-6 junio 2017), Madri, 3-6 jun. 2017.
Resumo: INTRODUCCIÓN: El trasplante renal es el tratamiento de elección para pacientes con insuficiencia renal crónica. Los inmunosupresores como los inhibidores de la calcineurina pueden estar asociados a efectos adversos. El Síndrome Doloroso por Inhibidores de la Calcineurina (SDIC) se caracteriza por dolores óseos simétricos, agudos e incapacitantes de miembros inferiores, e imágenes características en la resonancia magnética. Se presentan 4 casos de SDIC con retrasplante renal, uso de tacrolimus como inmunosupresor y diagnóstico por resonancia magnética. MATERIAL Y MÉTODOS: Cuatro pacientes (3 mujeres y 1 varón) que se retrasplantaron con riñones cadavéricos, entre marzo de 2014 y septiembre de 2015, presentaron fuertes dolores en miembros inferiores. Tacrolimus fue el principal agente inmunosupresor. Se realizaron resonancias magnéticas de miembros inferiores, se indicó tratamiento y ajuste en la dosis de tacrolimus. RESULTADOS: El SDIC comenzó a los 2 meses del trasplante y 2 semanas de la detección de niveles tóxicos de tacrolimus. El cuadro doloroso permaneció aproximadamente 2 semanas y fue cediendo. La localización fue exclusiva de miembros inferiores (rodillas, tobillos y pies). El dolor fue referido por los pacientes como agudo, punzante, incapacitante y empeoraba de pie. La resonancia magnética confirmó el diagnóstico, revelando un patrón de edema de médula ósea en meseta tibial y astrágalos. Todos los casos fueron reversibles con el tratamiento indicado. CONCLUSIONES: Reportamos la aparición de SDIC en 4 pacientes con retrasplante renal, uso de tacrolimus y buena evolución. El diagnóstico se basó en sospecha clínica, forma de presentación e imágenes típicas en las resonancias magnéticas

INTRODUCTION: Kidney transplant is the first-line therapy for chronic kidney disease. Immunosuppressants such as calcineurin-inhibitors may be associated with side effects. Calcineurin-inhibitor induced pain syndrome (CIPS) is characterized by symmetrical, severe and disabling bone pain in the lower limbs and can be easily identified by magnetic resonance imaging due to its typical patterns. Four CIPS cases after kidney retransplantation are presented, confirmed by MRI and with immunosuppressive therapy consisting of tacrolimus. METHODS: Four patients (3 females and 1 male) with cadaveric kidney retransplantation, performed between March 2014 and September 2015 showed intense pains in their lower limbs. Tacrolimus was the main immunosuppressive agent. MRI scans of the lower limbs were performed; tacrolimus treatment and dosage adjustment were indicated. RESULTS: CIPS started 2 months after transplantation and 2 weeks after detection of tacrolimus toxic levels. Pain lasted around 2 weeks and it gradually became less severe. Symptoms were exclusively located in the lower limbs (knees, ankles and feet). Patients described the pain as sharp, throbbing, disabling, and becoming worse when standing. MRI confirmed the diagnosis, revealing a pattern of bone marrow edema in tibial plateau and tali. All cases were reversible with the indicated treatment. CONCLUSIONS: This study registers 4 cases of CIPS in patients who had undergone kidney retransplantation and had taken tacrolimus with good response. Diagnosis was reached by clinical suspicion, form and location of pain, and characteristic patterns in the MRI scans
Descritores: Dor
Transtornos Somatoformes
Espectroscopia de Ressonância Magnética
Transplante de Rim
Tacrolimo
Calcineurina
Imunossupressores
Responsável: AR444.1 - BAN - Biblioteca Argentina de Nefrología Dr. Víctor R. Miatello


  8 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1046621
Autor: Mustafina, Gulgena Raisovna; Khismatullina, Zarema Rimovna.
Título: Modern aspects of rosacea therapy
Fonte: Prensa méd. argent;105(9 especial):576-581, oct 2019.
Idioma: en.
Resumo: This work is aimed at studying the problems of timely diagnostics and therapy of various forms of rosacea, identifying the factors that influence the compliance, prognosis, and quality of life of the patients, as well as the stages of combination therapy. The efficiency of rosacea therapy is determined by the timely identification of patients, as well as the clinical variety of the disease. Complex therapy of rosacea includes identification of the precipitating factors, basic skincare, and the use of systemic and local pathogenetic preparations. The "Gold Standard" of topical rosacea therapy is the antimicrobial and antiprotozoal drug called metronidazole. An important role in disease therapy is played by active cooperation between the doctor and the patient. Comprehensiveness, timeliness, and rationality of rosacea therapy are defined not only by the mechanisms of the disease development but also by aggravating factors, the need for basic care and photosensitivity of the patients
Descritores: Transtornos de Fotossensibilidade
Retinoides/uso terapêutico
Isotretinoína/uso terapêutico
Cooperação do Paciente
Tacrolimo/uso terapêutico
Rosácea/diagnóstico
Terapia Combinada
Metronidazol/uso terapêutico
Responsável: AR392.1 - Biblioteca


  9 / 120 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-598697
Autor: Leal, Maurício Telles Vargas; Matos, Marcos Almeida.
Título: Necrose avascular óssea na terapia imunossupressora em transplantados renais / Bone avascular necrosis in immunosuppressive therapy in kidney transplantation / Necrosis avascular ósea en la terapia inmunosupresora en transplantados renales
Fonte: Rev. baiana saúde pública;34(Supl 1), jul.-dez. 2010.
Idioma: pt.
Resumo: Introdução: Necrose avascular óssea NAV é a maior e mais debilitante complicação músculo-esquelética pós-transplante renal. A alta incidência de NAV no pós transplante renal tem sido historicamente associada a dosagens elevadas de corticosteroide. A introdução da terapia imunossupressora com ciclosporina A e tacrolimus permitiu a redução da dosagem de corticosteroide no pós-transplante renal e a incidência de NAV. Diversos estudos mostraram diferenças ainda não totalmente esclarecidas entre os fármacos imunossupressores a respeito do risco de desenvolvimento de NAV como efeito adverso. Objetivo Comparar o risco de NAV em pacientes transplantados renais que fizeram uso de tacrolimus ou ciclosporina A. Metodologia Realizou-se meta análise e, para a busca bibliográfica, foram utilizadas as bases de dados MedLine e Scielo. Resultados Os estudos incluídos foram dois ensaios clínicos randomizados controlados e um estudo de coorte retrospectivo. A análise dos três estudos incluídos na meta análise evidenciou que os pacientes tratados com ciclosporina A apresentavam maior frequência de NAV. A análise isolada do risco relativo de cada estudo mostrou uma redução do risco de desenvolvimento de necrose avascular no grupo tacrolimus, no entanto em apenas um dos estudos essa redução foi significativa. Conclusão A meta análise evidenciou que o uso de tacrolimus diminui o risco de desenvolvimento de osteonecrose avascular na terapia imunossupressora em transplantados renais.

Introduction: Bone avascular necrosis (BAN) is the largest and most debilitating musculoskeletal complication after renal transplantation. The high incidence of BAN in the post-kidney transplantation has been historically associated with high doses of corticosteroids. The introduction of immunosuppressive therapy with cyclosporin A and tacrolimus allowed a reduction in the dosage of corticosteroids after renal transplantation and in the incidence of BAN. Several studies have shown differences not yet fully understood among immunosuppressive drugs regarding the risk of BAN as adverse effects. Objective: To compare the risk of BAN in renal transplant patients who used tacrolimus or cyclosporine A. Methods: We conducted a meta-analysis, and for the literature search, we used the Medline and Scielo databases. Results: The two included studies were randomized controlled trials and a retrospective cohort study. The analysis of the three studies included in the meta-analysis showed that patients treated with cyclosporine A had higher frequency of BAN. A separate analysis of the relative risk of each study showed a reduced risk of developing avascular necrosis in the tacrolimus group, however in only one study this reduction was significant. Conclusion: The meta-analysis showed that the use of tacrolimus decreases the risk of avascular osteonecrosis in immunosuppressive therapy in kidney transplant patients.

Introducción: La Necrosis Avascular Ósea (NAV) es la mayor y más debilitante complicación músculo-esquelética post-transplante renal. La alta incidencia de NAV en el post-transplante renal ha sido historicamente asociada a dosajes elevados de corticosteroide. La introducción de la terapia imunosupresora con ciclosporina A y tacrolimus permitió la reducción del dosaje de corticosteroide en el post-transplante renal y la incidencia de NAV. Diversos estudios mostraron diferencias aún no totalmente esclarecidas entre los fármacos imunosupresores a respecto del riesgo de desarrollo de NAV como efecto adverso. Objetivo: Comparar el riesgo de NAV en pacientes transplantados renales que hicieron uso de tacrolimus o ciclosporina A. Metodología: Se realizó meta-análisis y, para la busca bibliográfica, fueron utilizadas las bases de datos MedLine y Scielo. Resultados: Los estudios incluidos fueron dos ensayos clínicos randomizados controlados y un estudio de corte retrospectivo. El análisis de los tres estudios incluidos en el meta-análisis evidenció que los pacientes tratados con ciclosporina A presentaban mayor frecuencia de NAV. El análisis aislado del riesgo relativo de cada estudio mostró una reducción del riesgo de desarrollo de necrosis avascular en el grupo tacrolimus, sin embargo, en apenas uno de los estudios esa reducción fue significativa. Conclusión: El meta-análisis evidenció que el uso de tacrolimus disminuyó el riesgo de desarrollo de osteonecrosis avascular en la terapia imunosupresora en transplantados renales.
Descritores: Osteonecrose
Tacrolimo/administração & dosagem
Insuficiência Renal
Responsável: BR15.1 - Biblioteca de Ciências Biomédicas


  10 / 120 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-877191
Autor: Rodrigues, Rodrigo Fellipe; Peres, Luis Alberto Batista; Miolo, Natália.
Título: Uso de tacrolimus na nefrite lúpica / Use of tacrolimus in lupus nephritis
Fonte: Rev. Soc. Bras. Clín. Méd;15(4):279-281, 20170000. [].
Idioma: pt.
Resumo: O lúpus eritematoso sistêmico é uma doença multissistêmica, de etiologia autoimune, que apresenta comprometimento renal em até 50% dos portadores. A nefrite lúpica é uma das mais sérias e comuns complicações do lúpus eritematoso sistêmico, especialmente nos pacientes não caucasianos. Drogas como ciclofosfamida (que faz a terapia de indução convencional, junto de corticosteroides), azatioprina, micofenolato de mofetila e hidroxicloroquina são essenciais para o tratamento desta complicação, porém ainda são necessárias outras opções terapêuticas em casos resistentes. O tacrolimus vem sendo utilizado recentemente no tratamento da nefrite lúpica, com escassas publicações a este respeito. Apresentamos revisão sobre o papel do tacrolimus na nefrite lúpica, utilizando artigos publicados nas principais bases de dados da literatura nacional e internacional, nos idiomas espanhol e inglês.(AU)

Systemic lupus erythematosus (SLE) is a multisystemic disease of autoimmune etiology that involves renal impairment in up to 50% of patients. Lupus nephritis (LN) is one of the most serious and common complications of systemic lupus erythematosus, especially in non-Caucasian patients. Drugs such as cyclophosphamide (which performs the conventional induction therapy along with corticosteroids), azathioprine, mycophenolate mofetil, and hydroxychloroquine are essential for the treatment of this complication, but other therapeutic options in resistant cases are also necessary. Tacrolimus has recently been used in the treatment of lupus nephritis, with few publications in this regard. We present a review of the role of tacrolimus in lupus nephritis using articles published in the main databases of national and international literature, in Spanish and English languages.(AU)
Descritores: Nefrite Lúpica/terapia
Tacrolimo/uso terapêutico
Lúpus Eritematoso Sistêmico
-Nefrite Lúpica/complicações
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: BR33.1 - Divisão Técnica de Biblioteca e Documentação



página 1 de 12 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde